-5%
Glimepiride, the active ingredient in Glimirid, belongs to the sulfonylurea class of antidiabetic medications. It works primarily by stimulating the release of insulin from the functioning beta cells of the pancreas. Glimepiride also enhances the sensitivity of beta cells to glucose, improving insulin secretion in response to normal physiological glucose levels. Additionally, Glimepiride has extrapancreatic effects, such as reducing basal glucose production in the liver and increasing peripheral tissue sensitivity to insulin, which further helps in lowering blood sugar levels. The hypoglycemic effect of a single dose can last up to 24 hours in non-fasting diabetic patients.
Indications: Glimirid is prescribed as an additional treatment alongside diet and exercise for managing blood glucose levels in patients with Type II Diabetes Mellitus (non-insulin-dependent diabetes), where controlling hyperglycemia through diet and exercise alone is insufficient. It can be used in combination with metformin if diet, exercise, and either Glimirid or metformin alone are inadequate in controlling blood sugar. Additionally, Glimirid can be used alongside insulin therapy when blood glucose levels cannot be sufficiently controlled by diet, exercise, and an oral hypoglycemic agent. It’s important to note that combining Glimirid with insulin may increase the risk of hypoglycemia.